title: Drug delivery systems for the future.
abstract: Parenteral drug delivery systems have the potential to make drugs both safer and more effective. While research in this field has been active for over 30 years, the current fiscal constraints of health care delivery add a greater degree of urgency to finding a working system. The three competing technologies currently under development include prodrug or zymogen-like systems, simple soluble macromolecular systems, and complex particulate multicomponent systems. In this review, the advantages, disadvantages, and areas for further development of these three basic technology systems are compared and contrasted; the biophysical constraints are considered; and a model solution system using surface modified nanocrystalline ceramics is described.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles School of Medicine.
authors.forename: H J
authors.initials: HJ
authors.lastname: Hnatyszyn
authors.forename: N
authors.initials: N
authors.lastname: Kossovsky
authors.forename: A
authors.initials: A
authors.lastname: Gelman
authors.forename: E
authors.initials: E
authors.lastname: Sponsler
mesh_terms: D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D055592:Biophysical Phenomena; D001703:Biophysics; D002214:Capsules; D002516:Ceramics; D016503:Drug Delivery Systems / Q000639:trends*; D005544:Forecasting; D006023:Glycoproteins; D007263:Infusions, Parenteral / Q000639:trends; D008081:Liposomes; D046911:Macromolecular Substances; D008422:Materials Testing; D011108:Polymers; D011355:Prodrugs; D011994:Recombinant Proteins; D013678:Technology, Pharmaceutical / Q000639:trends*; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D002214:Capsules; D006023:Glycoproteins; D008081:Liposomes; D046911:Macromolecular Substances; D011108:Polymers; D011355:Prodrugs; D011994:Recombinant Proteins